Sun Pharmaceutical Industries Ltd.
NSE: SUNPHARMA
Healthcare · Drug Manufacturers - Specialty & Generic
₹1,760.00 last close on 9 Oct 2026 +0.01%
Research updated
Apollo Hospitals Enterprise Ltd.
NSE: APOLLOHOSPHealthcareMedical Care Facilities
- Last close
- ₹8,027.50
- Day change
- +₹361.50 (+4.72%)vs
- Market cap
- ₹1.17 lakh crIndian rupees
- Research updated
- 1 report
About Apollo Hospitals Enterprise
Apollo Hospitals Enterprise Ltd. is a diversified healthcare services company that operates a broad network of hospitals, pharmacies, diagnostic centres, and digital health platforms across India and select international markets. Its core business spans multispecialty hospital care, primary and preventive care, retail pharmacy services, and diagnostics, supported by telemedicine and other technology-enabled healthcare offerings. The company serves patients through integrated care delivery across cardiology, oncology, neurology, orthopaedics, critical care, gastroenterology, and transplant services, making it a major provider in both acute and routine healthcare. Apollo Hospitals Enterprise Ltd. also offers hospital-based services, consultancy, training, and health-related support solutions, giving it a wide role in the healthcare value chain. Headquartered in Chennai, India, Apollo Hospitals Enterprise Ltd. is recognized as one of the leading integrated healthcare platforms in the market.
- Sector
- Healthcare
- Industry
- Medical Care Facilities
- Listing
- NSE: APOLLOHOSP
- Chief executive
- Dr. Madhu Sasidhar
- Employees
- 44,008
- Headquarters
- Chennai, India
- ISIN
- INE437A01024
- Website
- apollohospitals.com
Public research
The latest report on Apollo Hospitals Enterprise opens with Individual or above
Mool’s latest report on Apollo Hospitals Enterprise, of 4 Oct 2026, has no section published on the open web.
With Individual or above
What the full research on Apollo Hospitals Enterprise includes
Every piece of Mool’s research is built the same way: a researched evidence base, analyses that build on each other, a research model and a report with the call.
The report and Mool’s call
- The 12-month rating and target
- The 3-month view
- Mool's estimates beside the street's
- The claims the view rests on, and what would change it
The analyses, among them
- Business model & financial foundationWhat the company does and how it makes money, its structure, five years of financials and the metrics that matter for it.
- Future earnings & financial modelForecasts built from the drivers that move the business, by scenario, beside the street's.
- Fundamental valuation & 12-month thesisWhat the business is worth on several methods, what the market already prices in and the 12-month thesis that follows.
The research model
The model behind the report: the company’s history, the drivers that move it, its forecasts by scenario and the valuation the 12-month target comes from.
See Mool’s call and the full research
Individual or above opens every piece of research Mool has published. A new account can start with 10 days of Pro, or of Firm on a work email address. No card needed.
Report history
Reports on Apollo Hospitals Enterprise
- Research reportLatest
Same sector
More research in Healthcare
Divi's Laboratories Ltd.
NSE: DIVISLAB
Healthcare · Drug Manufacturers - Specialty & Generic
₹9,340.00 last close on 9 Oct 2026 −0.22%Research updated
Torrent Pharmaceuticals Ltd.
NSE: TORNTPHARM
Healthcare · Drug Manufacturers - Specialty & Generic
₹4,656.90 last close on 9 Oct 2026 +0.86%Research updated
Zydus Lifesciences Ltd.
NSE: ZYDUSLIFE
Healthcare · Drug Manufacturers - Specialty & Generic
₹1,117.50 last close on 9 Oct 2026 +0.49%Research updated
Lenskart Solutions Limited
NSE: LENSKART
Healthcare · Medical Instruments & Supplies
₹677.65 last close on 9 Oct 2026 +3.62%Research updated
Emcure Pharmaceuticals Ltd.
NSE: EMCURE
Healthcare · Drug Manufacturers - Specialty & Generic
₹1,833.50 last close on 9 Oct 2026 −0.97%Research updated
Prices are the last close on the NSE, 9 Oct 2026. Research from Mool’s report of 4 Oct 2026; page updated 12 Oct 2026.
Mool’s research is written by AI agents and published by Mool Capital Private Limited, a SEBI-registered Research Analyst, registration INH000012449, which is responsible for it. This page shows factual company information; it carries no rating and is not investment advice for any individual. Investment in securities market are subject to market risks. Read all the related documents carefully before investing. Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. Read the disclosures.